(Q44492712)

3 December 2017

Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats (English)

1 reference

3 December 2017

1 reference

Yossi Gilgun-Sherki

1

1 reference

3 December 2017

Eldad Melamed

series ordinal

2

1 reference

3 December 2017

Ilan Ziv

series ordinal

3

1 reference

3 December 2017

Daniel Offen

series ordinal

4

1 reference

3 December 2017

1 July 2003

1 reference

Basic and Clinical Pharmacology and Toxicology

3 December 2017

1 reference

3 December 2017

93

1 reference

3 December 2017

1

1 reference

3 December 2017

54-56

1 reference

Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics

3 December 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

The pharmacology and mechanism of action of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

A 6-hydroxydopamine-induced selective parkinsonian rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

Na+ channels as targets for neuroprotective drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

Selective depression of low-release probability excitatory synapses by sodium channel blockers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0773.2003.930108.X

7 January 2021

10.1034/J.1600-0773.2003.930108.X

Identifiers

DOI

1 reference

3 December 2017

1 reference